Journal Article

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program

Mosenzon, Ofri, Fernández Landó, Laura, Patel, Hiren, Cui, Xuewei, O’Neill, Ciara, Lingvay, Ildiko, Brown, Katelyn

2023

Overview

Background Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/ glucagon-like peptide-1 receptor agonist, is approved in the United States, Europe and Japan for the treatment of type 2 diabetes. Across the SURPASS-1 to -5 clinical studies, tirzepatide 5, 10 and 15 mg demonstrated significant improvements in glycated haemoglobin A1c (HbA1c) (− 1.9 to − 2.6%), body weight (− 6.6 to − 13.9%) and systolic blood pressure (SBP) (− 2.8 to − 12.6 mmHg) at the end of study treatment. Methods Post-hoc mediation analyses were conducted to evaluate weight-loss dependent and weight-loss independent effects of tirzepatide on SBP reductions across the 5 SURPASS studies. The safety population (all randomized patients who took at least 1 dose of study drug) of each study was analyzed. Additional analyses were conducted at individual study level or pooled across 5 SURPASS trials. Results The difference in mean SBP change from baseline at 40 weeks (total effect) between the tirzepatide and comparator groups was − 1.3 to − 5.1 mmHg (tirzepatide 5 mg), − 1.7 to − 6.5 mmHg (tirzepatide 10 mg) and − 3.1 to − 11.5 mmHg (tirzepatide 15 mg). These SBP reductions were primarily mediated through weight loss, with different degrees of contributions from weight-loss independent effects across the different trials. In the SURPASS-4 study, which enrolled patients with established cardiovascular disease, weight-loss independent effects explained 33% to 57% of difference in SBP change between tirzepatide and insulin glargine groups. In a pooled analysis of the SURPASS-1 to -5 studies, there was a significant (p < 0.001) but weak correlation (r = 0.18 to 0.22) between change in body weight and SBP. Reductions in SBP with tirzepatide were not dependent on concomitant antihypertensive medications at baseline as similar reductions were observed whether participants were receiving them or not (interaction p = 0.77). The largest SBP reductions were observed in the highest baseline category (> 140 mmHg), while those in the first quartile of baseline SBP category (< 122 mmHg) observed no further decrease in SBP. Conclusions Tirzepatide-induced SBP reduction was primarily mediated through weight loss, with different degrees of contributions from weight-loss independent effects across the different trials. SBP reduction was not dependent on antihypertensive medication use but dependent on baseline SBP value, alleviating theoretical concerns of hypotension.

• Publisher: BioMed Central,Springer Nature B.V,BMC
• Subject: Angiology / Antidiabetics / Antihypertensive Agents - adverse effects / Antihypertensives / Blood Pressure / Body Weight / Body weight loss / Cardiology / Cardiovascular disease / Cardiovascular diseases / Clinical trials / Demographics / Diabetes / Diabetes mellitus (non-insulin dependent) / Diabetes Mellitus, Type 2 - diagnosis / Diabetes Mellitus, Type 2 - drug therapy / Drug dosages / Gastric Inhibitory Polypeptide - therapeutic use / GIP protein / GLP-1 receptor agonists / Glucagon / Glucagon-like peptide 1 / Glucagon-Like Peptide-1 Receptor - agonists / Glucose / Hemoglobin / Humans / Hypertension / Hypoglycemic Agents - adverse effects / Hypotension / Hypotension - chemically induced / Hypotension - complications / Hypotension - drug therapy / Insulin / Laboratories / Mediation analysis / Medicine / Medicine & Public Health / Patients / Population studies / Systolic blood pressure / Tirzepatide / Weight Loss / Weight-loss dependent effects / Weight-loss independent effects